LUX-Head & Neck 4: Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapy
- First Posted Date
- 2014-05-06
- Last Posted Date
- 2019-03-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 36
- Registration Number
- NCT02131155
- Locations
- 🇨🇳
1200.162.86013 Boehringer Ingelheim Investigational Site, Jinan, China
🇨🇳1200.162.86007 Boehringer Ingelheim Investigational Site, Chengdu, China
🇰🇷1200.162.82001 Boehringer Ingelheim Investigational Site, Seoul, Korea, Republic of
Bioequivalence Study of Telmisartan Between Telmisartan 80 mg/Amlodipine 5 mg/Hydrochlorothiazide 12.5 mg (T80/A5/H12.5 mg) Fixed-dose Combination (FDC) Tablet and T80/H12.5 mg Tab and A5 mg (Encap A2.5 mg Tab x2) Concomitant Use
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2014-05-02
- Last Posted Date
- 2017-04-12
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 72
- Registration Number
- NCT02129192
- Locations
- 🇯🇵
Boehringer Ingelheim Investigational Site, Tokyo, Hachioji, Japan
Multiple Rising Oral Doses of BI 1060469 in Healthy Subjects and Mild Asthma Patients
- Conditions
- Asthma
- Interventions
- Drug: BI 1060469 HealthyDrug: Placebo to BI 1060469Drug: BI 1060469 asthmaticsDrug: Placebo to BI 1060469 asthmatics
- First Posted Date
- 2014-04-30
- Last Posted Date
- 2015-08-14
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 131
- Registration Number
- NCT02126865
- Locations
- 🇩🇪
1333.2.1 Boehringer Ingelheim Investigational Site, Berlin, Germany
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 1026706 in Male and Female Healthy Subjects and Patients With Osteoarthritis of the Knee
- First Posted Date
- 2014-04-30
- Last Posted Date
- 2019-03-25
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 58
- Registration Number
- NCT02126826
- Locations
- 🇩🇪
1320.2.2 Boehringer Ingelheim Investigational Site, Berlin, Germany
BI 836845 in Estrogen Receptor Positive Metastatic Breast Cancer
- First Posted Date
- 2014-04-28
- Last Posted Date
- 2022-02-03
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 164
- Registration Number
- NCT02123823
- Locations
- 🇰🇷
National Cancer Center, Goyang, Korea, Republic of
🇨🇳National Taiwan University Hospital, Taipei, Taiwan
🇦🇹LKH-Univ. Hospital Graz, Graz, Austria
Pharmacokinetic Single Dose Trial of Empagliflozin in Children and Adolescents With Type 2 Diabetes Mellitus
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2014-04-23
- Last Posted Date
- 2016-09-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 27
- Registration Number
- NCT02121483
- Locations
- 🇿🇦
1245.87.27003 Boehringer Ingelheim Investigational Site, Bellville, South Africa
🇿🇦1245.87.27002 Boehringer Ingelheim Investigational Site, Pretoria, South Africa
🇲🇽1245.87.52001 Boehringer Ingelheim Investigational Site, Chihuahua, Mexico
Bioequivalence of a FDC Tablet of Linagliptin/Metformin (2.5mg/750mg) Extended Release in Healthy Subjects
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2014-04-23
- Last Posted Date
- 2016-08-04
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 74
- Registration Number
- NCT02121509
- Locations
- 🇩🇪
1288.10.1 Boehringer Ingelheim Investigational Site, Ingelheim, Germany
A 4 Week Study With BI 144807 in Patients >= 50 Years With Wet Age Related Macular Degeneration
- First Posted Date
- 2014-04-23
- Last Posted Date
- 2016-06-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 14
- Registration Number
- NCT02121522
- Locations
- 🇩🇪
1313.20.49003 Boehringer Ingelheim Investigational Site, Tübingen, Germany
🇩🇪1313.20.49002 Boehringer Ingelheim Investigational Site, Leipzig, Germany
🇩🇪1313.20.49004 Boehringer Ingelheim Investigational Site, Bonn, Germany
Bioequivalence Study of Telmisartan Between T80/A5/H12.5 mg FDC Tablet and T80/A5 mg Tab and H12.5 mg Tab Concomitant Use
- Conditions
- Healthy
- Interventions
- Drug: T80/A5 mg FDC tabletDrug: H12.5 mg tabletDrug: T80/A5/H12.5 mg FDC tabletDrug: H12.5 mf tablet
- First Posted Date
- 2014-04-23
- Last Posted Date
- 2017-04-12
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 72
- Registration Number
- NCT02121535
- Locations
- 🇯🇵
Boehringer Ingelheim Investigational Site, Kanagawa, Yokohama, Japan
A Study to Investigate the Phototoxic Potential of Faldaprevir
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2014-04-15
- Last Posted Date
- 2014-06-25
- Lead Sponsor
- Boehringer Ingelheim
- Registration Number
- NCT02114671
- Locations
- 🇬🇧
1241.42.44001 Boehringer Ingelheim Investigational Site, Edinburgh, United Kingdom